Compare Levi Strauss & Co. (LEVI) vs Eli Lilly And Co (LLY) Price & Performance

Levi Strauss (LEVI) trades at $24.03, down 1.35% over the past day, yet maintains a bullish technical trend with consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.28, exceeding expectations of $0.24, and raised its full-year outlook. Strong fundamentals include a 61.72% gross margin and 9.66% net income margin, supported by a digital strategy driving direct-to-consumer growth. Analyst consensus is overwhelmingly bullish with an 83.33% buy rating and a $28.00 price target, implying significant upside from current levels.

Outlook remains positive given earnings momentum and dividend increases, but risks include tariff pressures and foreign exchange volatility noted in recent reports. The stock's valuation at a P/E of 17.4 appears reasonable relative to profitability, though competitive and macroeconomic headwinds warrant monitoring for sustained growth.

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.